482 related articles for article (PubMed ID: 8157196)
1. Elevated serum levels of neopterin and soluble interleukin-2 receptor in patients with ovarian cancer.
Gadducci A; Ferdeghini M; Malagnino G; Prontera C; Fanucchi A; Annicchiarico C; Bianchi R; Fioretti P; Facchini V
Gynecol Oncol; 1994 Mar; 52(3):386-91. PubMed ID: 8157196
[TBL] [Abstract][Full Text] [Related]
2. Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor alpha levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma.
Sedlaczek P; Frydecka I; Gabryś M; Van Dalen A; Einarsson R; Harłozińska A
Cancer; 2002 Nov; 95(9):1886-93. PubMed ID: 12404282
[TBL] [Abstract][Full Text] [Related]
3. Serum soluble interleukin-2 receptor (sIL-2R) assay in cervical and endometrial cancer. Preliminary data.
Ferdeghini M; Gadducci A; Prontera C; Marrai R; Malagnino G; Annicchiarico C; Fioretti P; Bianchi R
Anticancer Res; 1993; 13(3):709-13. PubMed ID: 8317901
[TBL] [Abstract][Full Text] [Related]
4. Prognostic relevance of soluble interleukin-2 receptors in patients with ovarian tumors.
Gebauer G; Rieger M; Jäger W; Lang N
Anticancer Res; 1999; 19(4A):2509-11. PubMed ID: 10470184
[TBL] [Abstract][Full Text] [Related]
5. Effects of granulocyte-macrophage colony stimulating factor on soluble interleukin-2 receptor serum levels and their relation to neopterin and tumor necrosis factor-alpha in cancer patients.
Crispino S; Lissoni P; Ardizzoia A; Rovelli F; Perego MS; Grassi MG; Barni S; Pittalis S; Tancini G
J Biol Regul Homeost Agents; 1993; 7(3):92-4. PubMed ID: 8135145
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of tumor necrosis factor (TNF), soluble receptors for TNF (55- and 75-kDa sTNFr), and soluble CD14 (sCD14) in epithelial ovarian cancer.
Gadducci A; Ferdeghini M; Castellani C; Annicchiarico C; Gagetti O; Prontera C; Bianchi R; Facchini V
Gynecol Oncol; 1995 Aug; 58(2):184-8. PubMed ID: 7542621
[TBL] [Abstract][Full Text] [Related]
7. Serum concentrations of neopterin, soluble interleukin 2 receptor, and soluble tumor necrosis factor receptor in Wegener's granulomatosis.
Nassonov EL; Samsonov MY; Tilz GP; Beketova TV; Semenkova EN; Baranov A; Wachter H; Fuchs D
J Rheumatol; 1997 Apr; 24(4):666-70. PubMed ID: 9101499
[TBL] [Abstract][Full Text] [Related]
8. [Serum soluble interleukin-2 receptor levels in patients with renal cell carcinoma: a comparison of values before and after surgery].
Tsukamoto S; Ishikawa S; Yamauchi A; Saitou S
Hinyokika Kiyo; 2000 Oct; 46(10):695-9. PubMed ID: 11215193
[TBL] [Abstract][Full Text] [Related]
9. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
[TBL] [Abstract][Full Text] [Related]
10. Soluble interleukin-2 receptor, intercellular adhesion molecule-1 and interleukin-10 serum levels in patients with melanoma.
Boyano MD; Garcia-Vázquez MD; López-Michelena T; Gardeazabal J; Bilbao J; Cañavate ML; Galdeano AG; Izu R; Díaz-Ramón L; Raton JA; Díaz-Pérez JL
Br J Cancer; 2000 Oct; 83(7):847-52. PubMed ID: 10970683
[TBL] [Abstract][Full Text] [Related]
11. Soluble interleukin-2 receptor in stage I-III melanoma.
Ottaiano A; Leonardi E; Simeone E; Ascierto PA; Scala S; Calemma R; Bryce J; Caracò C; Satriano RA; Gianfranco N; Franco R; Botti G; Castello G
Cytokine; 2006 Feb; 33(3):150-5. PubMed ID: 16517174
[TBL] [Abstract][Full Text] [Related]
12. [Neopterin and a soluble interleukin-2 receptor in patients with systemic lupus erythematodes].
Horák P; Hermanová Z; Ordeltová M; Faltýnek L; Kusá L; Budíková M; Vavrdová V; Opíchalová D; Ciferská H; Scudla V
Vnitr Lek; 2004 Jun; 50(6):422-7. PubMed ID: 15346634
[TBL] [Abstract][Full Text] [Related]
13. Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer.
Hurteau JA; Woolas RP; Jacobs IJ; Oram DC; Kurman CC; Rubin LA; Nelson DL; Berchuck A; Bast RC; Mills GB
Cancer; 1995 Nov; 76(9):1615-20. PubMed ID: 8635066
[TBL] [Abstract][Full Text] [Related]
14. Serum levels of interleukin-18 (IL-18) and soluble interleukin-2 receptor (sIL-2R) in lung cancer.
Naumnik W; Chyczewska E; Kovalchuk O; Tałałaj J; Izycki T; Panek B
Rocz Akad Med Bialymst; 2004; 49():246-51. PubMed ID: 15631351
[TBL] [Abstract][Full Text] [Related]
15. Serum soluble interleukin-2 receptor assay in epithelial ovarian cancer.
Ferdeghini M; Gadducci A; Prontera C; Malagnino G; Fanucchi A; Annicchiarico C; Facchini V; Bianchi R
Tumour Biol; 1993; 14(5):303-9. PubMed ID: 8235309
[TBL] [Abstract][Full Text] [Related]
16. [Clinical significance of serum soluble interleukin-2 receptor level in patients with non-Hodgkin's lymphoma].
Shimomura Y; Tsurumi H; Sawada M; Yamada T; Hara T; Fukuno K; Goto H; Moriwaki H
Rinsho Ketsueki; 1999 Aug; 40(8):639-45. PubMed ID: 10496038
[TBL] [Abstract][Full Text] [Related]
17. Value of serum CA125 levels in patients with high-risk, early stage epithelial ovarian cancer.
Kang WD; Choi HS; Kim SM
Gynecol Oncol; 2010 Jan; 116(1):57-60. PubMed ID: 19818996
[TBL] [Abstract][Full Text] [Related]
18. Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases.
Riisbro R; Stephens RW; Brünner N; Christensen IJ; Nielsen HJ; Heilmann L; von Tempelhoff GF
Gynecol Oncol; 2001 Sep; 82(3):523-31. PubMed ID: 11520150
[TBL] [Abstract][Full Text] [Related]
19. [Usefulness of the measurement of serum soluble IL-2 receptor alpha chain levels in clinical monitoring of non-Hodgkin lymphoma].
Setoyama Y; Imai J; Ishikawa T; Sakaida H; Takaori-Kondo A; Kawamata S; Uchiyama T
Rinsho Byori; 1994 Aug; 42(8):834-42. PubMed ID: 7933620
[TBL] [Abstract][Full Text] [Related]
20. The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients.
Begum FD; Høgdall CK; Kjaer SK; Christensen L; Blaakaer J; Bock JE; Glud E; Høyer-Hansen G; Ring-Larsen H; Høgdall EV
Anticancer Res; 2004; 24(3b):1981-5. PubMed ID: 15274388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]